Kanad Das

Kanad joined the Boehringer Ingelheim Venture Fund in 2018 from Merck (MSD) where he was Director, Business Development and Licensing in their West Coast Innovation Hub. He led efforts in Immuno-Oncology, Cardiovascular and Metabolic Diseases and Ophthalmology in the preclinical space up to human proof of concept. Kanad started his career at Genentech as a post-doctoral fellow, then going to KAI Pharmaceuticals as a medicinal chemist. There he was an inventor of Parsabiv, approved in 2017 for the treatment of Secondary Hyperparathyroidism. After KAI, Kanad worked at Stanford University’s SPARK program, an academic accelerator designed to take basic science discoveries and bring them to fundable assets. He Received his Ph.D. in Chemistry from the University of Massachusetts, Amherst and a B.Sc. in Chemistry from UC Berkeley.